Regenerative Medicine for the Aging Brain

In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson’s disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. In this context, cell reprogramming offers novel therapeutic possibilities for the treatment of these devastating diseases. In effect, the generation of induced pluripotent stem cells (iPSCs) from somatic cells demonstrated that adult mammalian cells can be reprogrammed to a pluripotent state by the overexpression of a few embryonic transcription factors (TF). This discovery fundamentally widened the research horizon in the fields of disease modeling and regenerative medicine. Although it is possible to re-differentiate iPSCs to specific somatic cell types, the tumorigenic potential of contaminating iPSCs that failed to differentiate, increases the risk for clinical application of somatic cells generated by this procedure. Therefore, reprogramming approaches that bypass the pluripotent stem cell state are being explored. A method called lineage reprogramming has been recently documented. It consists of the direct conversion of one adult cell type into another by transgenic expression of multiple lineage-specific TF or microRNAs. Another approach, termed direct reprogramming, features several advantages such as the use of universal TF system and the ability to generate a rejuvenated multipotent progenitor cell population, able to differentiate into specific cell types in response to a specific differentiation factors. These novel approaches offer a new promise for the treatment of pathologies associated with the loss of specific cell types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons in the early stages of AD. The above topics are reviewed here.

Read Full Article HERE

Contact us at stemcells@enlivenarchive.org

Journal Website: http://www.enlivenarchive.org/stem-cell-research-regenerative-medicine/

Clinical Impact of Anti-Endothelial Cell Antibodies in Kidney and Pancreas Transplantation

Background: Anti-endothelial cell antibodies (AECA) have been associated with graft dysfunction and rejection, but lack of scalable, cheap testing has hindered routine screening. Indirect immunofluorescence on human umbilical vein endothelial cells (HUVEC) aims to fill this niche, and a high incidence of severe multiple rejections has been reported in a large study of deceased-donor kidney transplant recipients.

Methods: We retrospectively studied 119 kidney transplants and 21 pancreas transplants consecutively performed in 128 recipients at our Centre.

Results: 13% showed positive pretransplant AECA. Of them, 47% showed negativization of AECA at various posttransplant times. At a median follow-up of 14 months (range : 6-24), patients with positive pretransplant AECA showed a higher risk of biopsy-proven acute cell-mediated pancreas rejection (OR = 24; P = 0.02); post-transplant persistence of AECA correlated with an even higher risk of pancreas rejection (OR = 78 ; P = 0.01). No correlation between pretransplant AECA and risk of kidney rejection or graft loss was found. De novo AECA developed in 4% of all patients, but did not correlate with any transplant-related event.

Conclusion: Our study demonstrates a lack of importance of pretransplant and de novo AECA screening in kidney transplantation. Larger studies on pancreas transplantation will be necessary to confirm the relevance in such setting.

Please find the entire article HERE

Contact us at surgery-transplantation@enlivenarchive.org 

Journal Website: http://www.enlivenarchive.org/surgery-and-transplantation/